Generate Biomedicines, Inc. (GENB)
14.34
+0.35
(+2.50%)
USD |
NASDAQ |
Oct 09, 16:00
14.34
0.00 (0.00%)
After-Hours: 20:00
Generate Biomedicines Enterprise Value : 1.445B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 1.445B |
| October 08, 2026 | 1.400B |
| October 07, 2026 | 1.346B |
| October 06, 2026 | 1.375B |
| October 05, 2026 | 1.389B |
| October 02, 2026 | 1.361B |
| October 01, 2026 | 1.375B |
| September 30, 2026 | 1.532B |
| September 29, 2026 | 1.583B |
| September 28, 2026 | 1.518B |
| September 25, 2026 | 1.548B |
| September 24, 2026 | 1.656B |
| September 23, 2026 | 1.724B |
| September 22, 2026 | 1.845B |
| September 21, 2026 | 1.835B |
| September 18, 2026 | 1.804B |
| September 17, 2026 | 1.801B |
| September 16, 2026 | 1.616B |
| September 15, 2026 | 1.682B |
| September 14, 2026 | 1.658B |
| September 11, 2026 | 1.622B |
| September 10, 2026 | 1.579B |
| September 09, 2026 | 1.596B |
| September 08, 2026 | 1.645B |
| September 04, 2026 | 1.708B |
| Date | Value |
|---|---|
| September 03, 2026 | 1.701B |
| September 02, 2026 | 1.693B |
| September 01, 2026 | 1.631B |
| August 31, 2026 | 1.564B |
| August 28, 2026 | 1.572B |
| August 27, 2026 | 1.628B |
| August 26, 2026 | 1.675B |
| August 25, 2026 | 2.219B |
| August 24, 2026 | 1.878B |
| August 21, 2026 | 1.673B |
| August 20, 2026 | 1.656B |
| August 19, 2026 | 1.782B |
| August 18, 2026 | 1.668B |
| August 17, 2026 | 1.618B |
| August 14, 2026 | 1.611B |
| August 13, 2026 | 1.533B |
| August 12, 2026 | 1.541B |
| August 11, 2026 | 1.436B |
| August 10, 2026 | 1.493B |
| August 07, 2026 | 1.446B |
| August 06, 2026 | 1.387B |
| August 05, 2026 | 1.464B |
| August 04, 2026 | 1.437B |
| August 03, 2026 | 1.445B |
| July 31, 2026 | 1.401B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 9.941B |
| Intellia Therapeutics, Inc. | 1.466B |
| Prime Medicine, Inc. | 738.55M |
| Moderna, Inc. | 85.92B |
| Arrowhead Pharmaceuticals, Inc. | 8.631B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.26M |
| Revenue (Quarterly) | 6.314M |
| Total Expenses (Quarterly) | 73.57M |
| EPS Diluted (Quarterly) | -0.5243 |
| Gross Profit Margin (Quarterly) | 48.94% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -32.21% |
| Normalized Earnings Yield | -32.19 |